ClinicalTrials.gg
WithdrawnNCT01773174Updated Oct 26, 2015

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

A Phase 2 interventional study of dabigatran etexilate in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Withdrawn at 8 sites in United States. Open to participants aged 1 Year to 2 Years. Per ClinicalTrials.gov, last updated 2015-10-26.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
1 Year to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
17th of 17
0 · median 148
Started
2013
with 2 others
Phase 2
7 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 17th largest by enrollment, is one of 3 that started in 2013, is one of 7 in phase 2, and was the 9th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 1 Year to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

Study will assess PK/PD parameters and safety and tolerability of the study medication in this age group

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
1 Year to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. males or females 1 to less than 2 years of age
  2. objective diagnosis of primary venous thromboembolism
  3. completion of planned treatment course with low molecular weight heparin or oral anticoagulant for primary venous thromboembolism
  4. written by parent (legal guardian) and patient assent (if applicable)

Exclusion criteria

Exclusion criteria:

  1. weight less than 9 kg
  2. conditions associated with increased risk of bleeding
  3. patients who have any condition that would not allow safe participation in study Note: Further exclusion criteria apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    dabigatran etexilate

    single dose treatment with dabigatran oral solution

    Drug: dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Ecarin clotting time (ECT)

    Time frame: one day

  2. Factor IIa inhibition

    Time frame: one day

  3. Incidence of all bleeding events

    Time frame: 30 days

  4. Incidence of all adverse events

    Time frame: 30 days

  5. Plasma concentrations of total dabigatran

    Time frame: one day

  6. Plasma concentrations of free dabigatran

    Time frame: one day

  7. Plasma concentrations of BIBR 1048 BS (Base)

    Time frame: one day

  8. Plasma concentrations of BIBR 951 BS

    Time frame: one day

  9. Plasma concentrations of BIBR 1087 SE (Acid)

    Time frame: one day

  10. Activated prothrombin time (aPTT)

    Time frame: one day

Secondary outcomes

  1. Global assessment of tolerability will be summarized across all patients in the treated set

    Time frame: 30 days

  2. Patient assessment of taste will be summarized across all patients in the treated set

    Time frame: one day

  3. Changes in laboratory and clinical parameters

    Time frame: 30 days

07

Study locations

8 sites
  • 1160.145.00010 Boehringer Ingelheim Investigational Site
    Sacramento, California, United States
  • 1160.145.00009 Boehringer Ingelheim Investigational Site
    Louisville, Kentucky, United States
  • 1160.145.00008 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts, United States
  • 1160.145.00012 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 1160.145.00007 Boehringer Ingelheim Investigational Site
    Newark, New Jersey, United States
  • 1160.145.0006 Boehringer Ingelheim Investigational Site
    Pittsburgh, Pennsylvania, United States
  • 1160.145.00001 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1160.145.00011 Boehringer Ingelheim Investigational Site
    Spokane, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2013
First posted
Jan 23, 2013
Start
Jan 2013
Primary completionEst.
Dec 2015
CompletionEst.
Dec 2015
Last update
Oct 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01773174
Responsible party
Sponsor
First posted
Jan 23, 2013
Start date
Jan 2013
Primary completion
Dec 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Oct 26, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion